Want to see HK:1863 full AI Analyst Report?
Top Page
China Longevity Group Co. Ltd.
(1863)
Select Model
Select Model
Rating:50Neutral
Price Target:―
Action:Reiterated
Date:07/01/26
The score is held back primarily by weaker financial performance—margin/return compression since the 2021 peak, increased leverage, and inconsistent cash generation with frequently negative free cash flow. Valuation appears moderate (P/E ~19.3), but missing dividend data limits support. Technical indicators were not provided, so momentum/trend confirmation cannot be incorporated.
Positive Factors
Sustained Profitability
The company remains profitable despite recent pressure, providing a durable earnings base to fund operations and strategic reinvestment. Persistent profitability supports debt servicing and operational continuity, giving management time to address margin and cash conversion issues.
Negative Factors
Rising Leverage
Leverage rising materially to ~0.9 reduces financial flexibility and raises refinancing and interest-rate exposure. Higher debt amplifies earnings volatility and restricts funding for capex or M&A, making the company more sensitive to profit shortfalls and macro shocks.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Profitability
The company remains profitable despite recent pressure, providing a durable earnings base to fund operations and strategic reinvestment. Persistent profitability supports debt servicing and operational continuity, giving management time to address margin and cash conversion issues.
Read all positive factors
China Longevity Group Co. Ltd. (1863) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
N/A
Dividend Yield5.03%
Average Volume (3M)N/A
Price to Earnings (P/E)23.0
Beta (1Y)N/A
Revenue Growth6.49%
EPS Growth-5.55%
CountryHK
EmployeesN/A
SectorGeneral
Sector StrengthN/A
IndustryIndustrial Materials
Share Statistics
EPS (TTM)0.05
Shares Outstanding852,612,500
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)1.32
Price to Sales (P/S)0.89
P/FCF Ratio565.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Longevity Group Co. Ltd. Business Overview & Revenue Model
Company Description
China Longevity Group operates within the reinforced materials industry, engaging comprehensively in the design, development, production, and distribution of its specialized products. These offerings include advanced polymer-processed polyester fa...
China Longevity Group Co. Ltd. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
49
Neutral
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.17B | 1.17B | 933.93M | 926.62M | 1.44B |
| Gross Profit | 203.90M | 202.74M | 186.04M | 146.32M | 260.47M |
| EBITDA | 106.46M | 127.29M | 127.75M | 122.09M | 195.87M |
| Net Income | 43.19M | 55.55M | 63.00M | 46.19M | 106.93M |
Balance Sheet | |||||
| Total Assets | 1.98B | 1.94B | 1.71B | 1.33B | 1.39B |
| Cash, Cash Equivalents and Short-Term Investments | 178.41M | 83.35M | 64.36M | 90.58M | 77.99M |
| Total Debt | 724.45M | 680.75M | 619.57M | 332.50M | 255.45M |
| Total Liabilities | 1.11B | 1.11B | 951.79M | 688.27M | 831.66M |
| Stockholders Equity | 797.67M | 749.28M | 676.42M | 599.34M | 531.17M |
Cash Flow | |||||
| Free Cash Flow | 1.85M | -23.86M | -354.53M | -138.53M | 55.80M |
| Operating Cash Flow | 108.71M | 103.56M | -10.62M | 35.14M | 177.51M |
| Investing Cash Flow | -104.77M | -135.18M | -333.16M | -95.10M | -201.75M |
| Financing Cash Flow | 42.15M | 50.22M | 317.36M | 73.07M | 67.21M |
China Longevity Group Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.65B | 9.21 | 43.78% | 11.19% | -14.68% | -13.60% | |
67 Neutral | HK$352.42M | 10.76 | 4.28% | 7.86% | -2.78% | -24.77% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | HK$469.86M | -145.56 | -0.41% | ― | 3.16% | -101.02% | |
50 Neutral | ― | 22.96 | 5.57% | 5.03% | 6.49% | -5.55% | |
46 Neutral | HK$515.57M | -1.28 | -25.36% | 1.47% | -8.94% | -140.82% | |
40 Underperform | HK$1.22B | 85.71 | 0.48% | 1.02% | -3.26% | ― |
* General Sector Average
HK:1863
China Longevity Group Co. Ltd.
―
―
―
HK:1830
Perfect Medical Health Management Limited
1.27
-0.12
-8.90%
HK:2138
EC Healthcare
0.43
-0.39
-48.17%
HK:3869
Hospital Corporation of China Ltd
3.40
-3.40
-50.00%
HK:3886
Town Health International Medical Group Ltd.
0.17
-0.08
-32.30%
HK:0722
UMP Healthcare Holdings Limited
0.42
-0.03
-6.04%
China Longevity Group Co. Ltd. Corporate Events
China Longevity Group Wins Strong Shareholder Backing at 2026 AGM
Jun 12, 2026
Shareholders of China Longevity Group Company Limited approved all resolutions tabled at the annual general meeting held on 12 June 2026, including the company’s audited financial statements for the year ended 31 December 2025. The voting re...
China Longevity Clarifies AGM Proxy Deadlines and Confirms No Final Dividend for 2025
Apr 30, 2026
China Longevity Group Company Limited has issued a clarification related to its previously distributed proxy form and circular for the annual general meeting scheduled for 12 June 2026. The company confirms that, despite these corrections, the exi...
China Longevity Cites Healthy Operations as Trading Suspension and Regulatory Review Persist
Apr 30, 2026
China Longevity Group has provided an operational update, stating that its production, operations, and finances remain healthy while it continues to focus on research and development of new materials and products. This suggests the business itself...
China Longevity Group Sets 2026 AGM and Seeks Fresh Share Issuance Mandate
Apr 28, 2026
China Longevity Group Company Limited has called its annual general meeting for 12 June 2026 in Fuzhou, Fujian, where shareholders will review and approve the audited consolidated financial statements and directors’ and auditors’ repor...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.